Agaphelin modulates the activation of human bronchial epithelial cells induced by lipopolysaccharide and IL-4.

Agaphelin modulates the activation of human bronchial epithelial cells induced by lipopolysaccharide and IL-4. Immunobiology. 2020 Mar 18;:151937 Authors: Favarin DC, Pereira ABM, Francischetti IMB, da Silva MV, Rodrigues V, da Silva PR, Valenzuela JG, Teixeira DNS, Oliveira CJF, Rogério AP Abstract Sand fly saliva presents molecules with potential to development of compounds for treatment of inflammatory diseases. Agaphelin, isolated from the saliva of the mosquito Anopheles gambiae, demonstrates anti-inflammatory properties such as neutrophils chemotaxis inhibition. Here, we extend these results and evaluated the role of agaphelin (0.1-100 nM) in an in vitro model consisting in the activation of human bronchial epithelial cells (BEAS-2B) by IL-4 (50 ng/mL) or lipopolysaccharide (LPS; 10 ng/mL). Agaphelin is non-cytotoxic for BEAS-2B cells. Notably, agaphelin markedly reduces CCL2 and IL-8 production induced by IL-4 or LPS, without altering the IL-10 production. The TLR4 expression and STAT1 phosphorylation induced by LPS were inhibited by agaphlin. In addition, agaphelin decreased the phosphorylation of STAT6 induce by IL-4, whose effect was independent of IL-4-binding activity. Taken together, these findings identify agaphelin as a potential anti-inflammatory therapeutic agent for airway inflammations. PMID: 32201094 [PubMed - as supplied by publisher]
Source: Immunobiology - Category: Allergy & Immunology Authors: Tags: Immunobiology Source Type: research